SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go?
PFE 26.88+4.5%3:08 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Anthony Wong who wrote (7827)6/9/1999 2:50:00 PM
From: Anthony Wong   of 9523
 
Pfizer's Trovan Antibiotic Use Should Be Limited, FDA Says

Bloomberg News
June 9, 1999, 2:35 p.m. ET

Pfizer's Trovan Antibiotic Use Should Be Limited, FDA Says

Washington, June 9 (Bloomberg) -- Pfizer Inc.'s Trovan
antibiotic should only be used to treat patients with serious or
life threatening illness because of concerns about liver
problems, the U.S. Food and Drug Administration said.

The FDA said the drug's use -- especially the oral form of
the drug -- should be restricted. Spokeswoman Susan Cruzan said
the company was working to limit the distribution of the drug.

Last month, Pfizer, the U.S.'s No. 2 drugmaker, said that
Trovan would get a stricter label in the U.S. and Europe after
reports of five deaths and three liver transplants linked to use
of the drug.

Trovan is an important product for Pfizer, the No. 2 U.S.
drugmaker, and had sales of $160 million in 1998, its first year
on the market after being approved in December 1997.

Pfizer shares fell 1 to 110 in afternoon trading.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext